PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.68 Million USD | 157.69% |
| 2022 | 2.2 Million USD | 239.72% |
| 2021 | 648.86 Thousand USD | -42.25% |
| 2020 | 1.12 Million USD | 4404.05% |
| 2019 | 24.94 Thousand USD | 167.61% |
| 2018 | 9322.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.89 Million USD | -49.07% |
| 2024 Q2 | 799.61 Thousand USD | -72.36% |
| 2023 Q3 | 3.23 Million USD | -37.14% |
| 2023 Q1 | 4.75 Million USD | 115.6% |
| 2023 FY | 5.68 Million USD | 157.69% |
| 2023 Q2 | 5.14 Million USD | 8.24% |
| 2023 Q4 | 5.68 Million USD | 75.67% |
| 2022 Q3 | 5.97 Million USD | 974.77% |
| 2022 Q4 | 2.2 Million USD | -63.14% |
| 2022 FY | 2.2 Million USD | 239.72% |
| 2022 Q1 | 540.91 Thousand USD | -16.64% |
| 2022 Q2 | 556.37 Thousand USD | 2.86% |
| 2021 Q3 | 1.85 Million USD | 0.0% |
| 2021 FY | 648.86 Thousand USD | -42.25% |
| 2021 Q4 | 648.86 Thousand USD | -65.1% |
| 2020 Q2 | 26.86 Thousand USD | -89.25% |
| 2020 Q1 | 249.8 Thousand USD | 0.0% |
| 2020 FY | 1.12 Million USD | 4404.05% |
| 2020 Q4 | 1.12 Million USD | 0.0% |
| 2019 FY | 24.94 Thousand USD | 167.61% |
| 2018 FY | 9322.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -1798.982% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 0.969% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 61.345% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 81.802% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -76.41% |
| Better Therapeutics, Inc. | 22.94 Million USD | 75.241% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 80.191% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -52.408% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 72.35% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 73.108% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 91.185% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -141.338% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 91.999% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 78.27% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -7374.906% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 53.321% |
| Molecular Templates, Inc. | 35.38 Million USD | 83.946% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -29.939% |
| NexImmune, Inc. | 8.59 Million USD | 33.902% |
| Orgenesis Inc. | 14.55 Million USD | 60.965% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 51.869% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -4457.34% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -1348.104% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 98.799% |
| Statera Biopharma, Inc. | 21.16 Million USD | 73.167% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 43.786% |
| Trevena, Inc. | 40.6 Million USD | 86.011% |
| Vaxxinity, Inc. | 44.35 Million USD | 87.193% |
| Vaccinex, Inc. | 3.63 Million USD | -56.442% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -14224.201% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 89.98% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -922.18% |